Suppr超能文献

慢性阻塞性肺疾病患者血液嗜酸性粒细胞、临床特征与死亡率之间的关系

Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD.

作者信息

Zysman Maeva, Deslee Gaëtan, Caillaud Denis, Chanez Pascal, Escamilla Roger, Court-Fortune Isabelle, Nesme-Meyer Pascale, Perez Thierry, Paillasseur Jean-Louis, Pinet Christophe, Jebrak Gilles, Roche Nicolas, Burgel Pierre-Régis

机构信息

Pulmonary Dpt, Nancy, Inserm U955, team 04, Créteil, France.

Pulmonary Dpt, Maison Blanche University Hospital, INSERM U903, Reims, France.

出版信息

Int J Chron Obstruct Pulmon Dis. 2017 Jun 20;12:1819-1824. doi: 10.2147/COPD.S129787. eCollection 2017.

Abstract

In patients with COPD, there is controversy regarding the association of blood eosinophil (Eos) levels with 1) exacerbation frequency and 2) the effect of inhaled corticosteroids for prevention of exacerbations. To determine whether Eos define subgroups of patients exhibiting attributes of COPD clinical phenotypes, we compared clinical features and mortality rates in COPD patients from the Initiatives BPCO French cohort categorized using different thresholds of blood Eos levels. The following data were collected at inclusion: medical and smoking history, occupational exposures, dyspnea, cough and sputum production, exacerbations in the previous year, history of allergy and asthma, nasal symptoms, body mass index, St George Respiratory Questionnaire (SGRQ) total score, post-bronchodilator spirometry, comorbidities, and medications. Three-year survival between groups was compared using Kaplan-Meier analysis. Three sets of analyses were performed to compare patients with ≥2% versus <2%, ≥3% versus <3%, and ≥4% versus <4% Eos. Eos was available in 458 patients (mean age: 62 years, 72% male, mean forced expiratory volume in 1 second: 51% pred), including 235 patients with Eos ≥2% (49%), 149 with Eos ≥3% (33%), and 90 with Eos ≥4% (20%). For all cutoffs, there was no difference between Eos+ and Eos- groups in univariate analyses except for diabetes and SGRQ score (more frequent and more impaired, respectively, in lower Eos categories). In particular, there was no difference in exacerbation rate, history of asthma, or three-year survival. In conclusion, regardless of the cutoff, Eos+ COPD patients exhibited no specific characteristic in terms of symptoms, lung function, exacerbation rate, and prognosis. These findings suggest that the association of higher Eos with exacerbations reported in previous studies could be population specific, which does not support generalizing the use of Eos as a biomarker for COPD phenotyping.

摘要

在慢性阻塞性肺疾病(COPD)患者中,关于血液嗜酸性粒细胞(Eos)水平与以下两方面的关联存在争议:1)急性加重频率;2)吸入性糖皮质激素预防急性加重的效果。为了确定Eos是否能界定出具有COPD临床表型特征的患者亚组,我们比较了法国慢性阻塞性肺疾病队列研究中根据不同血液Eos水平阈值分类的COPD患者的临床特征和死亡率。纳入研究时收集了以下数据:病史和吸烟史、职业暴露、呼吸困难、咳嗽和咳痰情况、前一年的急性加重情况、过敏和哮喘病史、鼻部症状、体重指数、圣乔治呼吸问卷(SGRQ)总分、支气管扩张剂后肺功能测定、合并症及用药情况。采用Kaplan-Meier分析比较各组之间的三年生存率。进行了三组分析,以比较Eos≥2%与<2%、≥3%与<3%、≥4%与<4%的患者。458例患者有Eos数据(平均年龄:62岁,72%为男性,平均第1秒用力呼气量:占预计值的51%),其中235例患者Eos≥2%(49%),149例患者Eos≥3%(33%),90例患者Eos≥4%(20%)。对于所有切点,单因素分析中Eos阳性和Eos阴性组之间除糖尿病和SGRQ评分外无差异(分别在Eos较低类别中更常见和受损更严重)。特别是,在急性加重率、哮喘病史或三年生存率方面没有差异。总之,无论切点如何,Eos阳性的COPD患者在症状、肺功能、急性加重率和预后方面均无特定特征。这些发现表明,先前研究中报道的较高Eos与急性加重之间的关联可能具有人群特异性,这并不支持将Eos作为COPD表型分析生物标志物的广泛应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3b4e/5490470/74ae5b3d9b20/copd-12-1819Fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验